{"id":264065,"date":"2026-06-04T11:36:00","date_gmt":"2026-06-04T15:36:00","guid":{"rendered":"https:\/\/news-you-need.com\/index.php\/2026\/06\/04\/alnylam-inceptive-ink-ai-deal-potentially-worth-2b\/"},"modified":"2026-06-04T11:45:22","modified_gmt":"2026-06-04T15:45:22","slug":"alnylam-inceptive-ink-ai-deal-potentially-worth-2b","status":"publish","type":"post","link":"https:\/\/news-you-need.com\/index.php\/2026\/06\/04\/alnylam-inceptive-ink-ai-deal-potentially-worth-2b\/","title":{"rendered":"Alnylam, Inceptive ink AI deal potentially worth $2B"},"content":{"rendered":"<p><a href=\"https:\/\/www.biopharmadive.com\/news\/alnylam-inceptive-ai-drug-discovery-rna-deal-artificial-intelligence\/822008\/\">Alnylam, Inceptive ink AI deal potentially worth $2B<\/a><\/p>\n<p><a href=\"https:\/\/www.biopharmadive.com\/news\/alnylam-inceptive-ai-drug-discovery-rna-deal-artificial-intelligence\/822008\/\">https:\/\/www.biopharmadive.com\/news\/alnylam-inceptive-ai-drug-discovery-rna-deal-artificial-intelligence\/822008\/<\/a><\/p>\n<p>Publish Date: <a href=\"publish_date]\">2026-06-04 11:36:00<\/a><\/p>\n<p>Source Domain: <a href=\"www.biopharmadive.com\">www.biopharmadive.com<\/a><\/p>\n<h3>Dive Brief:<\/h3>\n<ul>\n<li>Alnylam Pharmaceuticals is teaming up with biotechnology company Inceptive Nucleics, gaining access to artificial intelligence tools that it hopes will speed the discovery of new RNA-based therapies.<\/li>\n<li>The deal starts with $30 million up front, which includes cash and equity investments. Inceptive will also be eligible for payments based on reaching preclinical, regulatory and commercial sales milestones that could make the deal worth as much as $2 billion, the companies said\u00a0Wednesday.<\/li>\n<li>Alnylam is looking for the partnership to aid the \u201cambitious pipeline expansion\u201d that is part of a larger \u201cAlnylam 2030\u201d strategy announced earlier this year. \u201cThe goal is to help Alnylam prioritize the most promising molecules and improve experimental productivity,\u201d the companies said.<\/li>\n<\/ul>\n<h3>Dive Insight:<\/h3>\n<p>The deal is the latest example of how AI is reshaping the pharmaceutical industry. Proponents tout that the technology will help quickly zero in on therapies with the most promise. Inceptive CEO Jakob Uszkoreit goes a step further, saying his company\u2019s technology, in partnership with Alnylam, is \u201cchanging the way we understand and improve life.\u201d<\/p>\n<p>Alnylam takes aim at disease-causing proteins through a technique known as RNA interference. Inceptive\u2019s AI model is designed to learn patterns of biology, in theory offering insights that can yield the best targets for Alnylam. The companies said joint exploratory work showed \u201cexceptional performance within weeks\u201d in characterizing so-called small interfering RNA molecules.<\/p>\n<p>&#8220;Most drug design still works through a process of trial and error, testing thousands of molecules and hoping something sticks,\u201d Uszkoreit said in a statement. \u201cInceptive was built on a different premise: that life follows rules of such complexity that only AI can learn them.\u201d<\/p>\n<p>There are still questions about how much AI will change drug development. Large language models&#8230;<\/p>\n<p><a href=\"https:\/\/www.biopharmadive.com\/news\/alnylam-inceptive-ai-drug-discovery-rna-deal-artificial-intelligence\/822008\/\">Source<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Alnylam, Inceptive ink AI deal potentially worth $2B https:\/\/www.biopharmadive.com\/news\/alnylam-inceptive-ai-drug-discovery-rna-deal-artificial-intelligence\/822008\/ Publish Date: 2026-06-04 11:36:00 Source Domain:&#8230;<\/p>\n","protected":false},"author":1,"featured_media":264066,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/imgproxy.divecdn.com\/1MCWyHhguqpWVzOesZKtHHOMAeSL7X_TQqt4Q6c5iOI\/g:ce\/rs:fit:770:435\/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9BbG55bGFtX1Bob3RvXzEuSlBH.webp","fifu_image_alt":"","footnotes":""},"categories":[14],"tags":[],"class_list":["post-264065","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-artificial-intelligence"],"_links":{"self":[{"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/264065"}],"collection":[{"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/comments?post=264065"}],"version-history":[{"count":1,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/264065\/revisions"}],"predecessor-version":[{"id":264067,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/264065\/revisions\/264067"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/media\/264066"}],"wp:attachment":[{"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/media?parent=264065"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/categories?post=264065"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/tags?post=264065"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}